Deodhar A, Helliwell PS, Boehncke WH, et al. - A double-blind, randomised, placebo-controlled phase 3 trial was designed to analyze the utility and safety guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received tnfα inhibitor treatment (discover-1). This study conducted at 86 sites in 13 countries across Asia, Australasia, Europe, and North America and enrolled adults with active psoriatic arthritis (at least three swollen and three tender joints; and C-reactive protein ≥ 0·3 mg/dL) despite standard therapies. In this study, 624 patients were screened, of whom 381 were randomized and treated with guselkumab every 4 weeks (n=128), guselkumab every 8 weeks (n=127), or placebo (n=126) between Aug 28, 2017, to Aug 17, 2018. A favourable benefit–risk profile was found after prescribing guselkumab and this drug might be an effective treatment option for patients with active psoriatic arthritis.